A critical analysis of survival in idiopathic pulmonary arterial hypertension;Analyse critique des données de survie au cours de l'hypertension artérielle pulmonaire idiopathique

Presse Medicale

Volumn 39, Issue SUPPL. 1, 2010, Pages

  Humbert, Marc ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; ANTIHYPERTENSIVE AGENT;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; ESSENTIAL HYPERTENSION; FRANCE; HUMAN; LUNG TRANSPLANTATION; NATIONAL HEALTH ORGANIZATION; PATIENT CARE; PREDICTION; PULMONARY HYPERTENSION; REGISTRATION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; COMPLICATION; EPIDEMIOLOGY; HEART FAILURE; HYPERTENSION, PULMONARY; INCIDENCE; MORTALITY; PATIENT SELECTION; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; RARE DISEASE; REGISTER; STATISTICAL BIAS; SURVIVAL; UNITED STATES; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; BIAS (EPIDEMIOLOGY); DISEASE PROGRESSION; FRANCE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; LUNG TRANSPLANTATION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROGNOSIS; RARE DISEASES; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VASCULAR RESISTANCE;

EID: 77955978471     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(10)70006-3     Document Type: Article

References (19)

1. Galiè N., Hoeper M.M., Humbert M., Torbicki A., Vachiéry J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT).
2. Simonneau G., Robbins I., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classifi cation of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
3. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:13S-24S.
4. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
5. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., et al. Pulmonary arte rial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
6. Sztrymf B., Yaici A., Girerd B., Humbert M. Genes and pulmonary arterial hypertension. Respiration 2007, 74:123-132.
7. Hachulla E., Gressin V., Guillevin L., Carpentier P., Diot E., Sibilia J., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800.
8. Le Pavec J., Humbert M. Centres de référence « maladies rares respiratoires ». Presse Med 2007, 36:933-935.
9. Rich S., Danzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Int Med 1987, 107:216-223.
10. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Ann Int Med 1991, 115:343-349.
11. Humbert M., Sitbon O., Yaici A., Montani D., O'Callaghan D.S., Jaïs X., et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, [Epub ahead of print].
12. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010. [in press].
13. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1782.
14. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galiè N., et al. Survival with fi rst-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25:244-249.
15. Barst R.J., Galiè N., Naeije R., Simonneau G., Jeffs R., Arneson C., et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006, 28:1195-1203.
16. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of intravenous prostacyclin (epoprostenol) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296-302.
17. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Hervé P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
18. Galiè N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., Branzi A. A metaanalysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30:394-403.
19. Simonneau G., Rubin L.J., Galiè N., Barst R.J., Fleming T.R., Frost A.E., et al. Addition of sildenafi l to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Int Med 2008, 149:521-530.